Skip to main content

Table 1 Demographic and clinical parameters of enrolled patients(n=221)

From: Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis

Parameters Classification FFAs P
Low(n=106) High(n=115)
Age (years) >60 32 (30.19%) 40 (34.78%) 0.477
  ≤60 74 (69.81%) 75 (65.22%)  
Sex Male 65 (61.32%) 63 (54.78%) 0.343
  Female 41 (38.68%) 52 (45.22%)  
B symptoms Absent 88 (83.02%) 76 (66.09%) 0.005
  Present 18 (16.98%) 39 (33.91%)  
LDH >ULN 31 (29.25%) 71 (61.74%) <0.001
  Normal 75 (70.75%) 44 (38.26%)  
ECOG score 0-1 88 (83.02%) 83 (72.17%) 0.076
  2-4 18 (16.98%) 32 (27.83%)  
Ann Arbor Stage I-II 44 (41.51%) 38 (33.04%) 0.212
  III-IV 62 (58.49%) 77 (66.96%)  
Extranodal > 1 23 (21.70%) 41 (35.65%) 0.026
disease ≤ 1 83 (78.30%) 74 (64.35%)  
IPI Low risk (0-1) 52 (49.06%) 36 (31.30%) 0.008
  Low-intermediate risk (2) 28 (26.42%) 26 (22.61%)  
  High-intermediate risk (3) 16 (15.09%) 34 (29.57%)  
  High risk (4-5) 10 (9.43%) 19 (16.52%)  
Cell of origin GCB 36 (33.96%) 40 (34.78%) 0.416
  non-GCB 56 (52.83%) 66 (57.39%)  
  Undetermined 14 (13.21%) 9 (7.83%)